CCR2 antagonists

Current Topics in Medicinal Chemistry

Volumn 10, Issue 13, 2010, Pages 1278-1298

  Struthers, Mary ^a   Pasternak, Alexander ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABN 912; BMS 741672; CCX 140; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2; CNT 0888; CNTO 888; INCB 3284; INCB 8696; JNJ 17166864; MK 0812; MLN 1202; PF 04136309; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; BLOOD VESSEL OCCLUSION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LUNG FIBROSIS; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MONOCYTE; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PAIN; RHEUMATOID ARTHRITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; LIGANDS; MOLECULAR CONFORMATION; RECEPTORS, CCR2; STEREOISOMERISM;

EID: 77955604880     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610791561255     Document Type: Article

References (131)

1. Valente, A. J.; Graves, D. T.; Viallevalentin, C. E.; Delgado, R.; Schwartz, C. J. Purification of A monocyte chemotactic factor secreted by nonhuman primate vascular cells in culture. Biochemistry, 1988, 27(11), 4162-4168.
2. Deshmane, S. L.; Kremlev, S.; Amini, S.; Sawaya, B. E. Monocyte chemoattractant protein-1 (MCP-1): an overview. J. Interferon Cytokine Res., 2009, 29(6), 313-326.
3. Charo, I. F.; Myers, S. J.; Herman, A.; Franci, C.; Connolly, A. J.; Coughlin, S. R. Molecular-cloning and functional expression of 2 monocyte chemoattractant protein-1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc. Natl. Acad. Sci. USA, 1994, 97(7), 2752-2756.
4. Viola, A.; Luster, A. D. Chemokines and their receptors: Drug targets in immunity and inflammation. Ann. Rev. Pharm. Toxicol., 2008, 48, 171-197.
5. Tacke, F.; Randolph, G. J. Migratory fate and differentiation of blood monocyte subsets. Immunobiology, 2006, 277(6-8), 609-618.
6. Geissmann, F.; Jung, S.; Littman, D. R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity, 2003, 79(1), 71-82.
7. Kurihara, T.; Warr, G.; Loy, J.; Bravo, R. Defects in macrophage recruitment and host defense in mice lacking the CCR2 chemokine receptor. J. Exp. Med., 1997, 786(10), 1757-1762.
8. Boring, L.; Gosling, J.; Chensue, S. W.; Kunkel, S. L.; Farese, R. V.; Broxmeyer, H. E.; Charo, I. F. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest., 1997, 700(10), 2552-2561.
9. Bruhl, H.; Cihak, J.; Schneider, M. A.; Plachy, J.; Rupp, T.; Wenzel, I.; Shakarami, M.; Milz, S.; Ellwart, J. W.; Stangassinger, M.; Schlondorff, D.; Mack, M. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J. Immunol., 2004, 772(2), 890-898.
10. Tylaska, L. A.; Boring, L.; Weng, W.; Aiello, R.; Charo, I. F.; Rollins, B. J.; Gladue, R. P. CCR2 regulates the level of MCP-1/CCL2 in vitro and at inflammatory sites and controls T cell activation in response to alloantigen. Cytokine, 2002, 78(4), 184-190.
11. Mader, R. and Keystone, E. Optimizing treatment with biologics. J. Rheumatol., 2007, 34, 16-24.
12. Gaffo, A.; Saag, K. G.; Curtis, J. R. Treatment of rheumatoid arthritis. Am. J. Health Syst. Pharm., 2006, 63(24), 2451-2465.
13. Gartlehner, G.; Hansen, R. A.; Jonas, B. L.; Thieda, P.; Lohr, K. N. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J. Rheumatol., 2006, 33(12), 2398-2408.
14. Haringman, J. J.; Gerlag, D. M.; Zwinderman, A. H.; Smeets, T. J. M.; Kraan, M. C.; Baeten, D.; McInnes, I. B.; Bresnihan, B.; Tak, P. P. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis, 2005, 64(6), 834-838.
15. Dawson, J.; Miltz, W.; Mir, A. K.; Wiessner, C. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert. Opin. Ther. Targets., 2003, 7(1), 35-48.
16. Yang, Y. F.; Mukai, T.; Gao, P.; Yamaguchi, N.; Ono, S.; Iwaki, H.; Obika, S.; Imanishi, T.; Tsujimura, T.; Hamaoka, T.; Fujiwara, H. A non-peptide CCR5 antagonist inhibits collagen-induced arthritis by modulating T cell migration without affecting anti-collagen T cell responses. Eur. J. Immunol., 2002, 32(8), 2124-2132.
17. Baba, M.; Nishimura, O.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Iizawa, Y.; Shiraishi, M.; Aramaki, Y.; Okonogi, K.; Ogawa, Y.; Meguro, K.; Fujino, M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. USA, 1999, 96(10), 5698-5703.
18. Gao, P.; Zhou, X. Y.; Yashiro-Ohtani, Y.; Yang, Y. F.; Sugimoto, N.; Ono, S.; Nakanishi, T.; Obika, S.; Imanishi, T.; Egawa, T.; Na-gasawa, T.; Fujiwara, H.; Hamaoka, T. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J. Leukoc. Biol., 2003, 73(2), 273-280.
19. Gong, J. H.; Ratkay, L. G.; Waterfield, J. D.; Clark-Lewis, I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J. Exp. Med., 1997, 786(1), 131-137.
20. Gong, J. H.; Yan, R.; Waterfield, J. D.; Clark-Lewis, I. Post-onset inhibition of murine arthritis using combined chemokine antagonist therapy. Rheumatology (Oxford), 2004, 43(1), 39-42.
21. Ogata, H.; Takeya, M.; Yoshimura, T.; Takagi, K.; Takahashi, K. The role of monocyte chemoattractant protein-1 (MCP-1) in the pathogenesis of collagen-induced arthritis in rats. J. Pathol., 1997, 782(1), 106-114.
22. Schrier, D. J.; Schimmer, R. C.; Flory, C. M.; Tung, D. K.; Ward, P. A. Role of chemokines and cytokines in a reactivation model of arthritis in rats induced by injection with streptococcal cell walls. J. Leukoc. Biol., 1998, 63(3), 359-363.
23. Schimmer, R. C.; Schrier, D. J.; Flory, C. M.; Laemont, K. D.; Tung, D.; Metz, A. L.; Friedl, H. P.; Conroy, M. C.; Warren, J. S.; Beck, B.; Ward, P. A. Streptococcal cell wall-induced arthritis: requirements for IL-4, IL-10, IFN-gamma, and monocyte chemoat-tractant protein-1. J. Immunol, 1998, 760(3), 1466-1471.
24. Shahrara, S.; Proudfoot, A. E.; Park, C. C.; Volin, M. V.; Haines, G. K.; Woods, J. M.; Aikens, C. H.; Handel, T. M.; Pope, R. M. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J. Immunol., 2008, 780(5), 3447-3456.
25. Brodmerkel, C. M.; Huber, R.; Covington, M.; Diamond, S.; Hall, L.; Collins, R.; Leffet, L.; Gallagher, K.; Feldman, P.; Collier, P.; Stow, M.; Gu, X. M.; Baribaud, F.; Shin, N.; Thomas, B.; Burn, T.; Hollis, G.; Yeleswaram, S.; Solomon, K.; Friedman, S.; Wang, A. L.; Xue, C. B.; Newton, R. C.; Scherle, P.; Vaddi, K. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J. Immunol., 2005, 775(8), 5370-5378.
26. Quinones, M. P.; Ahuja, S. K.; Jimenez, F.; Schaefer, J.; Garavito, E.; Rao, A.; Chenaux, G.; Reddick, R. L.; Kuziel, W. A.; Ahuja, S. S. Experimental arthritis in CC chemokine receptor 2-null mice closely mimics severe human rheumatoid arthritis. J. Clin. Invest., 2004, 773(6), 856-866.
27. Quinones, M. P.; Estrada, C. A.; Kalkonde, Y.; Ahuja, S. K.; Kuz-iel, W. A.; Mack, M.; Ahuja, S. S. The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J. Mol. Med, 2005, 83(9), 672-681.
28. Quinones, M. P.; Jimenez, F.; Martinez, H.; Estrada, C. A.; Will-mon, O.; Dudley, M.; Kuziel, W. A.; Melby, P. C.; Reddick, R. L.; Ahuja, S. K.; Ahuja, S. S. CC chemokine receptor (CCR)-2 prevents arthritis development following infection by Mycobacterium avium. J. Mol. Med., 2006, 84(6), 503-512.
29. Bruhl, H.; Cihak, J.; Plachy, J.; Kunz-Schughart, L.; Niedermeier, M.; Denzel, A.; Rodriguez, Gomez M.; Talke, Y.; Luckow, B.; Stangassinger, M.; Mack, M. Targeting of Gr-1+,CCR2+ monocytes in collagen-induced arthritis. Arthritis Rheum, 2007, 56(9), 2975-2985.
30. Tanuma, N.; Sakuma, H.; Sasaki, A.; Matsumoto, Y. Chemokine expression by astrocytes plays a role in microglia/macrophage activation and subsequent neurodegeneration in secondary progressive multiple sclerosis. ActaNeuropathol, 2006, 772(2), 195-204.
31. Mahad, D.; Callahan, M. K.; Williams, K. A.; Ubogu, E. E.; Kivisakk, P.; Tucky, B.; Kidd, G.; Kingsbury, G. A.; Chang, A.; Fox, R. J.; Mack, M.; Sniderman, M. B.; Ravid, R.; Staugaitis, S. M.; Stins, M. F.; Ransohoff, R. M. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogene-sis. Brain, 2006, 729(Pt 1), 212-223.
32. Dzenko, K. A.; Song, L.; Ge, S.; Kuziel, W. A.; Pachter, J. S. CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2. Microvasc. Res., 2005, 70(1-2), 53-64.
33. Dimitrijevic, O. B.; Stamatovic, S. M.; Keep, R. F.; Andjelkovic, A. V. Effects of the chemokine CCL2 on blood-brain barrier permeability during ischemia-reperfusion injury. J. Cereb. Blood Flow Metab, 2006, 26(6), 797-810.
34. Fife, B. T.; Huffnagle, G. B.; Kuziel, W. A.; Karpus, W. J. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J. Exp. Med., 2000, 792(6), 899-905.
35. Gaupp, S.; Pitt, D.; Kuziel, W. A.; Cannella, B.; Raine, C. S. Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice - Susceptibility in multiple strains. Am. J. Pathol., 2003, 762(1), 139-150.
36. Buntinx, M.; Hermans, B.; Goossens, J.; Moechars, D.; Gilissen, R. A. H. J.; Doyon, J.; Boeckx, S.; Coesemans, E.; Van Lommen, G.; Van Wauwe, J. P. Pharmacological profile of JNJ-27141491 [(S)-3-[3,4-difluorophenyl)-propyl]-5-isoxazol-5-yl-2-thioxo-2,3-dihydro -1H-imidazole4-carboxyl acid methyl ester], as a noncom-petitive and orally active antagonist of the human chemokine receptor CCR2. J. Pharm. Exp. Therap, 2008, 327(1), 1-9.
37. Braddock, M. 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. Expert Opin. Investig. Drugs, 2007, 76(6), 909-917.
38. Szalai, C.; Kozma, G. T.; Nagy, A.; Bojszko, A.; Krikovszky, D.; Szabo, T.; Falus, A. Polymorphism in the gene regulatory region of MCP-1 is associated with asthma susceptibility and severity. J. Allergy Clin. Immun., 2001, 708(3), 375-381.
39. Szalai, C.; Duba, J.; Prohaszka, Z.; Kalina, A.; Szabo, T.; Nagy, B.; Horvath, L.; Csaszar, A. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis, 2001, 758(1), 233-239.
40. Boring, L.; Gosling, J.; Cleary, M.; Charo, I. F. Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 1998, 394(6696), 894-897.
41. Peters, W. and Charo, I. F. Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr. Opin. Lipidol., 2001, 72(2), 175-180.
42. Gu, L.; Okada, Y.; Clinton, S. K.; Gerard, C.; Sukhova, G. K.; Libby, P.; Rollins, B. J. Absence of monocyte chemoattractant pro-tein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell, 1998, 2(2), 275-281.
43. Ni, W. H.; Kitamoto, S.; Ishibashi, M.; Usui, M.; Inoue, S.; Hiasa, K.; Zhao, Q. W.; Nishida, K.; Takeshita, A.; Egashira, K. Monocyte chemoattractant protein-1 is an essential inflammatory mediator in angiotensin II-induced progression of established atherosclerosis in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol., 2004, 24(3), 534-539.
44. Ishibashi, M.; Hasa, K. I.; Zhao, Q.; Ohtani, K.; Kitamoto, S.; Egashira, K. Absence of monocyte chemoattractant protein-1 receptor CCR2 on monocytes supresses angiotensin II-induced progression of atherosclerosis in ApoE-deficient mice. Circulation, 2003, 708(17), 252-252.
45. Ishibashi, M.; Egashira, K.; Zhao, Q. W.; Hiasa, K.; Ohtani, K.; Ihara, Y.; Charo, I. F.; Kura, S.; Tsuzuki, T.; Takeshita, A.; Suna-gawa, K. Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler. Thromb. Vasc. Biol., 2004, 24(11), E174-E178.
46. Combadiere, C.; Potteaux, S.; Rodero, M.; Simon, T.; Pezard, A.; Esposito, B.; Merval, R.; Proudfoot, A.; Tedgui, A.; Mallat, Z. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation, 2008, 777(13), 1649-1657.
47. Gautier, E. L.; Jakubzick, C.; Randolph, G. J. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2009, 29(10), 1412-1418.
48. Tacke, F.; Alvarez, D.; Kaplan, T. J.; Jakubzick, C.; Spanbroek, R.; Llodra, J.; Garin, A.; Liu, J.; Mack, M.; van Rooijen, N.; Lira, S. A.; Habenicht, A. J.; Randolph, G. J. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J. Clin. Invest., 2007, 777(1), 185-194.
49. Olzinski, A. R.; Bernard, R. E.; Turner, G. H.; Karr, H.; Cornejo, C. A.; Aravindham, K.; Goodman, K. B.; Hoang, B.; Willette, R. N.; Macphee, C. H.; Jucker, B. M.; Sehon, C. A.; Gough, P. J. Pharmacological inhibition of CCR2 decreases macrophage infiltration in the aortic root of the huCCR2ki/apoE(-/-) Mouse: MRI assessment. Circulation, 2008, 778(18), S511-S511.
50. Aiello, R. J.; Perry, B. D.; Bourassa, P. A.; Robertson, A.; Weng, W. F.; Knight, D. R.; Smith, A. H.; Frederick, K. S.; Kalgutkar, A.; Gladue, R. P. CCR2 receptor blockade alters blood monocyte sub-populations but does not affect atherosclerotic lesions in apoE(-/-) mice. Atherosclerosis, 2010, 208(2), 370-375.
51. Egashira, K.; Zhao, Q.; Kataoka, C.; Ohtani, K.; Usui, M.; Charo, I. F.; Nishida, K.; Inoue, S.; Katoh, M.; Ichiki, T.; Takeshita, A. Importance of monocyte chemoattractant protein-1 pathway in neoin-timal hyperplasia after periarterial injury in mice and monkeys. Circ. Res., 2002, 90(11), 1167-1172.
52. Horvath, C.; Welt, F. G.; Nedelman, M.; Rao, P.; Rogers, C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res., 2002, 90(4), 488-494.
53. Jerath, M.; Liu, P.; Rojas, M.; Struthers, M.; DeMartino, J.; Lyons, K.; Peng, R. Q.; Yang, L. H.; Patel, D. Dual targeting of CCR2 and CX3CR1 in an arterial injury model of vascular inflammation. Clin. Immun, 2007, 723, S161-S162.
54. Subramanian, V.; Ferrante, A.W.J. Obesity, inflammation, and macrophages. Nestle Nutr. Workshop Ser. Pediatr. Program, 2009, 63, 151-159.
55. Christiansen, T.; Richelsen, B.; Bruun, J. M. Monocyte chemoat-tractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. (Lond), 2005, 29(1), 146-150.
56. Bruun, J. M.; Lihn, A. S.; Pedersen, S. B.; Richelsen, B. Monocyte chemoattractant protein-1 release is higher in visceral than subcutaneous human adipose tissue (AT): Implication of macrophages resident in the AT. J. Clin. Endocrinol. Metab., 2005, 90(4), 2282-2289.
57. Kim, C. S.; Park, H. S.; Kawada, T.; Kim, J. H.; Lim, D.; Hubbard, N. E.; Kwon, B. S.; Erickson, K. L.; Yu, R. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int. J. Obes. (Lond), 2006, 30(9), 1347-1355.
58. Bose, T.; Alvarenga, J. C.; Tejero, M. E.; Voruganti, V. S.; Proffitt, J. M.; Freeland-Graves, J. H.; Cole, S. A.; Comuzzie, A. G. Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. J. Med. Pri-matol, 2009, 38(6), 418-424.
59. Schernthaner, G. H.; Kopp, H. P.; Kriwanek, S.; Krzyzanowska, K.; Satler, M.; Koppensteiner, R.; Schernthaner, G. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes. Surg., 2006, 76(6), 709-715.
60. Weisberg, S. P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R. L.; Ferrante, A. W.; Jr. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest., 2003, 772(12), 1796-1808.
61. Lumeng, C. N.; Bodzin, J. L.; Saltiel, A. R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest., 2007, 777(1), 175-184.
62. Ito, A.; Suganami, T.; Yamauchi, A.; Degawa-Yamauchi, M.; Tanaka, M.; Kouyama, R.; Kobayashi, Y.; Nitta, N.; Yasuda, K.; Hirata, Y.; Kuziel, W. A.; Takeya, M.; Kanegasaki, S.; Kamei, Y.; Ogawa, Y. Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. J. Bi-ol. Chem, 2008, 283(51), 35715-35723.
63. Weisberg, S. P.; Hunter, D.; Huber, R.; Lemieux, J.; Slaymaker, S.; Vaddi, K.; Charo, I.; Leibel, R. L.; Ferrante, A. W. Jr. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest., 2006, 776(1), 115-124.
64. Inouye, K. E.; Shi, H.; Howard, J. K.; Daly, C. H.; Lord, G. M.; Rollins, B. J.; Flier, J. S. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes, 2007, 56(9), 2242-2250.
65. Chen, A. R.; Mumick, S.; Zhang, C. S.; Lamb, J.; Dai, H. Y.; Weingarth, D.; Mudgett, J.; Chen, H.; MacNeil, D. J.; Reitman, M. L.; Qian, S. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obesity Res, 2005, 73(8), 1311-1320.
66. Abbadie, C. Chemokines, chemokine receptors and pain. Trends Immunol.; 2005, 26(10), 529-534.
67. Menetski, J.; Mistry, S.; Lu, M.; Mudgett, J. S.; Ransohoff, R. M.; Demartino, J. A.; MacIntyre, D. E.; Abbadie, C. Mice overexpress-ing chemokine ligand 2 (CCL2) in astrocytes display enhanced no-ciceptive responses. Neuroscience, 2007, 749(3), 706-714.
68. Dansereau, M. A.; Gosselin, R. D.; Pohl, M.; Pommier, B.; Mechighel, P.; Mauborgne, A.; Rostene, W.; Kitabgi, P.; Beaudet, N.; Sarret, P.; Melik-Parsadaniantz, S. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J. Neurochem., 2008, 706(2), 757-769.
69. Jung, H. S.; Bhangoo, S.; Banisadr, G.; Freitag, C.; Ren, D. J.; White, F. A.; Miller, R. J. Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J. Neurosci., 2009, 29(25), 8051-8062.
70. Abbadie, C.; Lindia, J. A.; Cumiskey, A. M.; Peterson, L. B.; Mudgett, J. S.; Bayne, E. K.; Demartino, J. A.; MacIntyre, D. E.; Forrest, M. J. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc. Natl. Acad. Sci. USA, 2003, 700(13), 7947-7952.
71. Szabo, I.; Chen, X. H.; Xin, L.; Adler, M. W.; Howard, O. M.; Oppenheim, J. J.; Rogers, T. J. Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc. Natl. Acad. Sci. USA, 2002, 99(16), 10276-10281.
72. Pfizer Product Pipeline as of March 31, 2009. http://www.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf [Accessed 11/2009].
73. Batra, J. and Ghosh, B. Genetic contribution of chemokine receptor 2 (CCR2) polymorphisms towards increased serum total IgE levels in Indian asthmatics. Genomics, 2009, 94(3), 161-168.
74. Al Abdulhadi, S. A. and Al Rabia, M. W. Association and preferential transmission of the CCR2V64I polymorphism with absence of asthma in high-risk families. Saudi Med. J., 2008, 29(12), 1711-1718.
75. Chelbi, H.; Ghadiri, A.; Lacheb, J.; Ghandil, P.; Hamzaoui, K.; Hamzaoui, A.; Combadiere, C. A polymorphism in the CCL2 chemokine gene is associated with asthma risk: a case-control and a family study in Tunisia. Genes Immun., 2008, 9(7), 575-581.
76. Chan, C. K.; Kuo, M. L.; Yeh, K. W.; Ou, L. S.; Chen, L. C.; Yao, T. C.; Huang, J. L. Sequential evaluation of serum monocyte che-motactic protein 1 among asymptomatic state and acute exacerbation and remission of asthma in children. J. Asthma, 2009, 46(3), 225-228.
77. Rose, C. E. Jr.; Sung, S. S.; Fu, S. M. Significant involvement of CCL2 (MCP-1) in inflammatory disorders of the lung. Microcirculation, 2003, 70(3-4), 273-288.
78. Kim, Y.; Sung, S. S., Kuziel, W. A.; Feldman, S.; Fu, S. M.; Rose, C. E. Jr. Enhanced airway Th2 response after allergen challenge in mice deficient in CC chemokine receptor-2 (CCR2). J. Immunol., 2001, 766(8), 5183-5192.
79. Mellado, M.; Martin, de Ana, Gomez, L.; Martinez, C.; Rodriguez-Frade, J. M. Chemokine receptor 2 blockade prevents asthma in a cynomolgus monkey model. J. Pharmacol. Exp. Ther., 2008, 324(2), 769-775.
80. US National Institutes of Health. http://www.clinicaltrials.gov/ [Accessed 12/2009].
81. Bellini, A.; Mattoli, S. The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses. Lab. Invest., 2007, 87(9), 858-870.
82. Conti, I.; Rollins, B. J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol., 2004, 14(3), 149-154.
83. Garber, K. First results for agents targeting cancer-related inflammation. J. Natl. Cancer Inst., 2009, 101(16), 1110-1112.
84. Hede, K. Looking at cancer through an evolutionary lens. J. Natl. Cancer Inst., 2009, 101(16), 1108-1109.
85. Pease, J. E.; Horuk, R. Chemokine receptor antagonists: part 2. Expert Opin. Ther. Pat., 2009, 19(2), 199-221.
86. Pease, J. E. and Horuk, R. Chemokine receptor antagonists: Part 1. Expert Opin. Ther. Pat., 2009, 19(1), 39-58.
87. Dasse, O. A.; Evans, J. L.; Zhai, H. X.; Zou, D.; Kintigh, J. T.; Chan, F.; Hamilton, K.; Hill, E.; Eckman, J. B.; Higgins, P. J.; Vo-losov, A.; Collart, P.; Nicolas, J. M.; Kondru, R. K.; Schwartz, C. Novel, acidic CCR2 receptor antagonists: Lead optimization. Lett. DrugDes. Discov., 2007, 4(4), 263-271.
88. Xia, M.D.; Sui, Z. H. Recent developments in CCR2 antagonists. Expert Opin. Ther. Pat., 2009, 19(3), 295-303.
89. Peters, W.; Scott, H. M.; Chambers, H. F.; Flynn, J. L.; Charo, I.; Ernst, J. D. Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 2001, 98(14), 7958-7963.
90. Pasternak, A.; Marino, D.; Vicario, P. P.; Ayala, J. M.; Cascierri, M. A.; Parsons, W.; Mills, S. G.; MacCoss, M.; Yang, L. H. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists. J. Med. Chem., 2006, 49(16), 4801-4804.
91. Butora, G.; Morriello, G. J.; Kothandaraman, S.; Guiadeen, D.; Pasternak, A.; Parsons, W. H.; MacCoss, M.; Vicario, P. P.; Cas-cieri, M. A.; Yang, L. H. 4-amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties. Bioorg. Med. Chem. Lett., 2006, 16(18), 4715-4722.
92. Yang, L. H.; Butora, G.; Jiao, R. X.; Pasternak, A.; Zhou, C.; Parsons, W. H.; Mills, S. G.; Vicario, P. P.; Ayala, J. M.; Cascieri, M. A.; MacCoss, M. Discovery of 3-piperidinyl-1-cyclopentanecar-boxamide as a novel scaffold for highly potent CC chemokine receptor 2 antagonists. J. Med. Chem., 2007, 50(11), 2609-2611.
93. Butora, G.; Jiao, R.; Parsons, W. H.; Vicario, P. P.; Jin, H.; Ayala, J. M.; Cascieri, M. A.; Yang, L. H. 3-Amino-1-alkyl-cyclopentane carboxamides as small molecule antagonists of the human and mur-ine CC chemokine receptor 2. Bioorg. Med. Chem. Lett., 2007, 17(13), 3636-3641.
94. Kothandaraman, S.; Donnely, K. L.; Butora, G.; Jiao, R.; Pasternak, A.; Morriello, G. J.; Goble, S. D.; Zhou, C.; Mills, S. G.; MacCoss, M.; Vicario, P. P.; Ayala, J. M.; Demartino, J. A.; Struthers, M.; Cascieri, M. A.; Yang, L. H. Design, synthesis, and structure-activity relationship of novel CCR2 antagonists. Bioorg. Med. Chem. Lett., 2009, 19(6), 1830-1834.
95. Wisniewski, T.; Bayne, E. K.; Flanagan, J.; Shao, Q.; Wnek, R.; Matheravidathu, S.; Fischer, P.; Forrest, M. J.; Peterson, L. B.; Song, X.; Yang, L.; Demartino, J. A.; Struthers, M. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. J. Immunol. Methods, 2010, 352, 101-110.
96. Pasternak, A.; Goble, S. D.; Vicario, P. P.; Di Salvo, J.; Ayala, J. M.; Struthers, M.; Demartino, J. A.; Mills, S. G.; Yang, L. Potent heteroarylpiperidine and carboxyphenylpiperidine 1-alkyl-cyclopentane carboxamide CCR2 antagonists. Bioorg. Med. Chem. Lett., 2008, 18(3), 994-998.
97. Lagu, B.; Gerchak, C.; Pan, M.; Hou, C. F.; Singer, M.; Malaviya, R.; Matheis, M.; Olini, G.; Cavender, D.; Wachter, M. Potent and selective CC-chemokine receptor-2 (CCR2) antagonists as a potential treatment for asthma. Bioorg. Med. Chem. Lett., 2007, 17(15), 4382-4386.
98. Doyon, J.; Coesemans, E.; Boeckx, S.; Buntinx, M.; Hermans, B.; Van Wauwe, J. P.; Gilissen, R. A. H. J.; De Groot, A. H. J.; Corens, D.; Van Lommen, G. Discovery of potent, orally bioavail-able small-molecule inhibitors of the human CCR2 receptor. Chemmedchem, 2008, 3(4), 660-669.
99. Xia, M. D.; Hou, C.; Pollack, S.; Brackley, J.; DeMong, D.; Pan, M.; Singer, M.; Matheis, M.; Olini, G.; Cavender, D.; Wachter, M. Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists. Bioorg. Med. Chem. Lett., 2007, 17(21), 5964-5968.
100. Xia, M. D.; Hou, C. F.; Demong, D. E.; Pollack, S. R.; Pan, M.; Brackley, J. A.; Jain, N.; Gerchak, C.; Singer, M.; Malaviya, R.; Matheis, M.; Olini, G.; Cavender, D.; Wachter, M. Synthesis, structure - Activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists. J. Med. Chem., 2007, 50(23), 5561-5563.
101. Xia, M. D.; Hou, C. F.; DeMong, D.; Pollack, S.; Pan, M.; Brack-ley, J.; Singer, M.; Matheis, M.; Cavender, D.; Wachter, M. Substituted dipiperidine alcohols as potent CCR2 antagonists. Bioorg. Med. Chem. Lett., 2008, 18(12), 3562-3564.
102. Xia, M. G.; Hou, C. F.; DeMong, D.; Pollack, S.; Pan, M.; Singer, M.; Matheis, M.; Murray, W.; Cavender, D.; Wachter, M. Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists. Bioorg. Med. Chem. Lett., 2008, 18(24), 6468-6470.
103. Weisberg, S. P.; Hunter, D.; Huber, R.; Lemieux, J.; Slaymaker, S.; Vaddi, K.; Charo, I.; Leibel, R. L.; Ferrante, A. W. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J. Clin. Invest., 2006, 116(5), 1457-1457.
104. Shin, N.; Baribaud, F.; Wang, K.; Yang, G.; Wyenn, R.; Covington, M. B.; Feldman, P.; Gallagher, K.; Leffet, L.; Lo, Y. Y.; Wang, A.; Xue, C.-B.; Newton, R. C.; Scherle, P. A. Pharmacological characterization of INCB3344, a small molecule antagonist of human CCR2. Biochem. Biophys. Res. Commun., 2009, 387(2), 251-5.
105. Cherney, R. J.; Mo, R. W.; Meyer, D. T.; Nelson, D. J.; Lo, Y. C.; Yang, G.; Scherle, P. A.; Mandlekar, S.; Wasserman, Z. R.; Jezak, H.; Solomon, K. A.; Tebben, A. J.; Carter, P. H.; Decicco, C. P. Discovery of disubstituted cyclohexanes as a new class of CC chemokine receptor 2 antagonists. J. Med. Chem., 2008, 51(4), 721-724.
106. Cherney, R. J.; Brogan, J. B.; Mo, R. W.; Lo, Y. C.; Yang, G.; Miller, P. B.; Scherle, P. A.; Molino, B. F.; Carter, P. H.; Decicco, C. P. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists. Bioorg. Med. Chem. Lett., 2009, 19(3), 597-601.
107. Cherney, R. J.; Mo, R. W.; Meyer, D. T.; Voss, M. E.; Lo, Y. C.; Yang, G. J.; Miller, P. B.; Scherle, P. A.; Tebben, A. J.; Carter, P. H.; Decicco, C. P. Novel sulfone-containing di- and trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists. Bioorg. Med. Chem. Lett., 2009, 19(13), 3418-3422.
108. Singh, J. P.; Yu, X. H.; Wang, G. M.; Hamdouchi, C.; Kowala, M.; Zimmerman, K. A potent anti-inflammatory CCR2/CCR5 dual antagonist abrogates adipose inflammation and glucose intolerance, and reduces fat mass in a preclinical model of diet induced obesity. Circulation, 2008, 118(18), S503-S503.
109. Shiraishi, M.; Aramaki, Y.; Seto, M.; Imoto, H.; Nishikawa, Y.; Kanzaki, N.; Okamoto, M.; Sawada, H.; Nishimura, O.; Baba, M.; Fujino, M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J. Med. Chem., 2000, 43(10), 2049-2063.
110. Tokuyama, H.; Ueha, S.; Kurachi, M.; Matsushima, K.; Moriyasu, F.; Blumberg, R. S.; Kakimi, K. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int. Immunol., 2005, 17(8), 1023-1034.
111. Hall, S. E.; Mao, A.; Nicolaidou, V.; Finelli, M.; Wise, E. L.; Ned-jai, B.; Kanjanapangka, J.; Harirchian, P.; Chen, D.; Selchau, V.; Ribeiro, S.; Schyler, S.; Pease, J. E.; Horuk, R.; Vaidehi, N. Elucidation of Binding Sites of Dual Antagonists in the Human Chemokine Receptors CCR2 and CCR5. Mol. Pharm., 2009, 75(6), 1325-1336.
112. Horuk, R. OPINION Chemokine receptor antagonists: overcoming developmental hurdles. Nat. Rev. Drug Discov, 2009, 8(1), 23-33.
113. Bristol Myers Squibb pipeline. http://www.bms.com/research/pipeline/ [Accessed 11/2009].
114. Proudfoot, A. E. I. Is CCR2 the right chemokine receptor to target in rheumatoid arthritis? Arthritis Rheum., 2008, 58(7), 1889-1891.
115. Vauquelin, G.; Van Liefde, I.; Birzbier, B. B.; Vanderheyden, P. M. L. New insights in insurmountable antagonism. Fund. Clin. Pharm., 2002, 16(4), 263-272.
116. Vauquelin, G.; Van Liefde, I.; Vanderheyden, P. Models and methods for studying insurmountable antagonism. Trends Pharmacol. Sci., 2002, 23(11), 514-518.
117. Wyant, T.; Lackey, A.; Green, M. Validation of a flow cytometry based chemokine internalization assay for use in evaluating the pharmacodynamic response to a receptor antagonist. J. Trans. Med., 2008, 6, 76.
118. Beaulieu, A.; Hasler, F.; Mola, E. M.; Pavelka, K.; DeMartino, J.; Struthers, M.; Chen, P.; Koen, J.; Melian, A. The efficacy and safety of a CCR2 receptor antagonist in the treatment of rheumatoid arthritis (RA). Ann. Rheum. Dis, 2006, 65, 175-176.
119. Haringman, J. J.; Gerlag, D. M.; Smeets, T. J.; Baeten, D.; van den, Bosch F.; Bresnihan, B.; Breedveld, F. C.; Dinant, H. J.; Legay, F.; Gram, H.; Loetscher, P.; Schmouder, R.; Woodworth, T.; Tak, P. P. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum, 2006, 54(8), 2387-2392.
120. Vergunst, C. E.; Gerlag, D. M.; Lopatinskaya, L.; Klareskog, L.; Smith, M. D.; van den Bosch, F.; Dinant, H. J.; Lee, Y.; Wyant, T.; Jacobson, E. W.; Baeten, D.; Tak, P. P. Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum, 2008, 58(7), 1931-1939.
121. Swirski, F. K.; Libby, P.; Aikawa, E.; Alcaide, P.; Luscinskas, F. W.; Weissleder, R.; Pittet, M. J. Ly-6C(hi) monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest., 2007, 777(1), 195-205.
122. Tsou, C. L.; Peters, W.; Si, Y.; Slaymaker, S.; Aslanian, A. M.; Weisberg, S. P.; Mack, M.; Charo, I. F. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J. Clin. Invest., 2007, 777(4), 902-909.
123. Wang, Y.; Cui, L.; Gonsiorek, R.; Min, S.-H.; Anilkumar, G.; Rosenblum, S.; Kozlowski, J.; Lundell, D.; Fine, J. S.; Grant, E. P. CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune en-cephalomyelitis. J. Inflamm., 2009, 6, 32.
124. Sharrack, B.; Leach, T.; Jacobson, E.; Donaldson, D. D.; Xu, X.; Hu, M. Frequent MRI study of a novel CCR2 antagonist in relaps-ing-remitting multiple sclerosis. Ann. Neurol., 2007, 62, S74-S75.
125. Incyte pipeline. http://www.incyte.com/drugs_product_pipeline.html [Accessed 11/2009].
126. Davidson, M.; Lekstrom-Himes, J.; Gilbert, J.; Donaldson, D.; Lee, Y.; Hu, M.; Xu, J. MLN1202, a novel CCR2 antagonist, decreases C-reactive protein in patients at risk for atherosclerotic cardiovascular disease in a double blind placebo controlled study. Circulation, 2007, 776(16), II-172.
127. Chemocentryx company web site, CCR2 program. http://www.chemocentryx.com/product/CCR2.html [Accessed 11/2009].
128. Mason, V. L. Inflammation 2009-Ninth World Congress. Advances in inflammation research: part 1. 6-10 July 2009, Tokyo, Japan. Idrugs, 2009, 72(9), 529-531.
129. Haringman, J. J.; Gerlag, D. M.; Streets, T. J. M.; Baeten, D.; Bres-nihan, B.; Breedveld, F. C.; Gram, H.; Schmouder, R.; Woodworth, T.; Tak, P. P. A randomized placebo controlled trial with an anti-MCP-1 (CCL2) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum., 2004, 50(9), S238-S238.
130. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders. http://investor.millennium.com/phoenix.zhtml?c=80159&p=irol-newsArticle&ID=1073472&highlight=MLN1202 [Accessed 12/2009].
131. Pfizer product pipeline as of Sept 30, 2008. http://me-dia.pfizer.com/files/research/pipeline/2008_0930/pipeline_2008_0930.pdf [Accessed 12/2009].